Driehaus Capital Management

Venture Capital Active United States
Last updated 2026-06-18
Portfolio
2
in our dataset
Rounds participated
2
Rounds led
0
Rounds' value
$170.0M
total disclosed, rounds participated
Stages
—

Portfolio · 2

C2i Genomics
Whole-genome Cancer Treatment Intelligence Platform
1 round $100.0M committed Latest: 2021-04
DarioHealth
Digital Therapeutics for Treating Chronic Conditions
1 round $70.0M committed Latest: 2021-01

Investment activity

1 portfolio exit on record.

Portfolio by sector

Health Tech & Life Sciences2

Q&A

What is Driehaus Capital Management's most recent exit?
Driehaus Capital Management exited C2i Genomics in January 2024 through an acquisition by Veracyte for $95M.
Which sectors does Driehaus Capital Management primarily focus on for investments?
Driehaus Capital Management shows a concentration in the Health Tech & Life Sciences sector, with all of its portfolio companies and exits falling within this area.
Can you name some of Driehaus Capital Management's portfolio companies?
Driehaus Capital Management's portfolio includes C2i Genomics, which was acquired, and DarioHealth, which is publicly traded.
What is the typical investment range for Driehaus Capital Management?
Driehaus Capital Management typically invests in the range of $70M - $100M.
When did Driehaus Capital Management make its most recent investments?
Driehaus Capital Management made investments in January 2021 and April 2021.
What kind of funding stages has Driehaus Capital Management participated in?
Driehaus Capital Management has participated in B Round and PIPE funding stages.